-
Patent Agency Ranking
公开(公告)号：US10301292B2
公开(公告)日：2019-05-28
申请号：US15529816
申请日：2015-11-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Ryo Mizojiri , Hiroshi Banno , Moriteru Asano , Daisuke Tomita , Noriyuki Nii , Hironobu Maezaki , Michiko Tawada
IPC: C07D413/04 , C07D413/14 , A61K31/343 , A61K31/381 , A61K31/416 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/443 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/517 , A61K31/5377 , C07D231/56 , C07D333/56 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D263/54 , C07D498/04 , C07D307/81 , C07D263/57 , C12N15/09
Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
-
公开(公告)号：US09751885B2
公开(公告)日：2017-09-05
申请号：US14435085
申请日：2013-10-11
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Naoki Tomita , Daisuke Tomita , Yusuke Tominari , Shinichi Imamura , Shinji Morimoto , Takuto Kojima , Masashi Toyofuku , Yasushi Hattori , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D487/04 , C07C255/58 , C07C255/60 , C07D231/40 , C07C317/40 , C07C237/30 , C07C237/38 , C07C237/40 , C07C255/29 , A61K45/06 , C07D309/14 , C07D319/18 , C07D413/12 , C07D241/12 , C07D417/12 , C07D261/14 , C07D207/12 , C07D285/135 , C07D211/58 , C07D295/135 , C07D213/40 , C07D207/46 , C07D213/36 , C07D223/12 , C07D231/38 , C07D241/18 , C07D265/36 , C07D277/38 , C07D333/20 , C07D405/12 , C07D471/04 , C07D513/04
CPC classification number: C07D487/04 , A61K45/06 , C07C237/30 , C07C237/38 , C07C237/40 , C07C255/29 , C07C255/58 , C07C255/60 , C07C317/40 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/12 , C07D207/46 , C07D211/58 , C07D213/36 , C07D213/40 , C07D223/12 , C07D231/38 , C07D231/40 , C07D241/12 , C07D241/18 , C07D261/14 , C07D265/36 , C07D277/38 , C07D285/135 , C07D295/135 , C07D309/14 , C07D319/18 , C07D333/20 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04
Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.
-
公开(公告)号：US09682925B2
公开(公告)日：2017-06-20
申请号：US15005574
申请日：2016-01-25
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Naoki Tomita , Shigeo Kajii , Douglas Robert Cary , Daisuke Tomita , Shinichi Imamura , Ken Tsuchida , Satoru Matsuda , Ryujiro Hara
IPC: A61K31/167 , A61K31/36 , A61K31/366 , A61K31/40 , A61K31/402 , A61K31/4035 , A61K31/404 , A61K31/4184 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/451 , A61K31/495 , A61K31/55 , C07C233/80 , A61K31/381 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/4468 , C07D309/14 , C07C271/22 , C07D317/58 , C07D223/16 , C07D231/14 , C07D231/20 , C07D231/22 , C07D333/20 , C07D231/56 , C07D233/61 , C07D233/64 , C07D405/04 , C07D239/36 , C07D409/04 , C07D471/04 , C07D261/08 , C07D261/10 , C07D263/32 , C07D263/34 , C07C235/56 , C07D207/06 , C07C237/40 , C07D495/04 , C07D207/337 , C07D277/20 , C07D277/28 , C07D277/30 , C07D209/08 , C07D277/62 , C07D209/42 , C07D513/04 , C07D209/46 , C07D209/48 , C07D285/06 , C07D211/56 , C07D211/58 , C07D295/14 , C07D211/76 , C07D213/04 , C07D213/38 , C07D213/56 , C07D211/98 , C07D335/02 , C07C237/42 , C07C271/20 , C07D211/40 , C07D231/26 , C07D295/135 , C07D295/155
CPC classification number: C07C233/80 , A61K31/167 , A61K31/36 , A61K31/366 , A61K31/381 , A61K31/40 , A61K31/402 , A61K31/4035 , A61K31/404 , A61K31/4184 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/55 , C07C235/56 , C07C237/40 , C07C237/42 , C07C271/20 , C07C271/22 , C07C2601/02 , C07C2601/18 , C07C2602/08 , C07D207/06 , C07D207/337 , C07D209/08 , C07D209/42 , C07D209/46 , C07D209/48 , C07D211/40 , C07D211/56 , C07D211/58 , C07D211/76 , C07D211/98 , C07D213/04 , C07D213/38 , C07D213/56 , C07D223/16 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/26 , C07D231/56 , C07D233/61 , C07D233/64 , C07D239/36 , C07D261/08 , C07D261/10 , C07D263/32 , C07D263/34 , C07D277/20 , C07D277/28 , C07D277/30 , C07D277/62 , C07D285/06 , C07D295/135 , C07D295/14 , C07D295/155 , C07D309/14 , C07D317/58 , C07D333/20 , C07D335/02 , C07D405/04 , C07D409/04 , C07D471/04 , C07D495/04 , C07D513/04
Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q1, Q2, Q3 and Q4 are each a hydrogen atom or a substituent; Q1 and Q2, and Q3 and Q4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y1, Y2 and Y3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y1, and Y1 and Y2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z1, Z2 and Z3 are each H or a substituent, or a salt thereof.
-
公开(公告)号：US10252997B2
公开(公告)日：2019-04-09
申请号：US15563128
申请日：2016-03-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Ryo Mizojiri , Moriteru Asano , Daisuke Tomita , Hiroshi Banno , Michiko Tawada , Noriyuki Nii , Krista E. Gipson , Hironobu Maezaki , Shuntarou Tsuchiya , Mayumi Imai , Yuichiro Amano
IPC: C07D213/65 , A61K31/165 , A61K31/167 , A61K31/277 , A61K31/381 , A61K31/402 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/427 , A61K31/44 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/451 , A61K31/454 , A61K31/4965 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , C07D213/75 , C07D213/81 , C07D231/12 , C07D333/20 , C07D401/04 , C07D237/14 , C07D239/34 , C07D409/04 , C07D413/04 , C07D241/18 , C07D417/04 , C07C233/18 , C07C233/47 , C07D261/08 , C07D263/32 , C07D263/42 , C07D207/08 , C07D207/12 , C07D277/34 , C07D211/44 , C07D213/643 , C07D213/69 , C07C233/25 , C07C255/54 , C07D211/46 , C07D213/74 , C07D401/12 , C12N9/99 , C12N15/09
Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
-
公开(公告)号：US20150266881A1
公开(公告)日：2015-09-24
申请号：US14435085
申请日：2013-10-11
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Naoki Tomita , Daisuke Tomita , Yusuke Tominari , Shinichi Imamura , Shinji Morimoto , Takuto Kojima , Masashi Toyofuku , Yasushi Hattori , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D487/04 , C07D231/38 , C07C237/38 , C07C237/30 , C07D241/12 , C07D213/36 , C07D471/04 , C07D207/46 , C07D241/18 , C07D319/18 , C07D265/36 , C07D333/20 , C07D285/135 , C07D277/38 , C07D405/12 , C07D417/12 , C07D413/12 , C07D223/12 , C07D513/04 , C07C237/40
CPC classification number: C07D487/04 , A61K45/06 , C07C237/30 , C07C237/38 , C07C237/40 , C07C255/29 , C07C255/58 , C07C255/60 , C07C317/40 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/12 , C07D207/46 , C07D211/58 , C07D213/36 , C07D213/40 , C07D223/12 , C07D231/38 , C07D231/40 , C07D241/12 , C07D241/18 , C07D261/14 , C07D265/36 , C07D277/38 , C07D285/135 , C07D295/135 , C07D309/14 , C07D319/18 , C07D333/20 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04
Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.
Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物，可用作精神分裂症，阿尔茨海默病，帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物：其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1，R 2和R 3各自独立地为氢原子，任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合，与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合，与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。
-
-
-
-
Search Results
5
records
(took 0.026 seconds)
